Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/58043
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ozdemir, Melek | - |
dc.contributor.author | Dogu, Gamze Gokoz | - |
dc.contributor.author | Taskoylu, Burcu Yapar | - |
dc.contributor.author | Demiray, Atike Gökçen | - |
dc.contributor.author | Çakan Demirel, Burçin | - |
dc.contributor.author | Doğan, Tolga | - |
dc.contributor.author | Güçlü Kantar, Taliha | - |
dc.contributor.author | Yaren, Arzu | - |
dc.contributor.author | Degirmencioglu, Serkan | - |
dc.contributor.author | Tas, Semra | - |
dc.contributor.author | Yildiz, Bedriye Acikgoz | - |
dc.contributor.author | Ozel, Gamze Serin | - |
dc.date.accessioned | 2024-10-20T16:20:47Z | - |
dc.date.available | 2024-10-20T16:20:47Z | - |
dc.date.issued | 2024 | - |
dc.identifier.issn | 2587-0262 | - |
dc.identifier.uri | https://doi.org/10.4274/nkmj.galenos.2024.93898 | - |
dc.identifier.uri | https://hdl.handle.net/11499/58043 | - |
dc.description.abstract | Aim According to the information obtained from the World Health Organization database, the incidence of hepatocellular carcinoma (HCC) in Turkey increased by 17.78% between the years of 2018 and 2020. In this study, we investigated the prognostic value of albumin-bilirubin (ALBI) score and lymphocyte-associated inflammation markers on overall survival (OS) and progression-free survival (PFS) in advanced hepatocellular carcinoma. Materials and Methods Data of 141 patients with advanced HCC were included in this study. ALBI score and lymphocyte-associated inflammatory marker were calculated. As a result, the prognostic significance of these tests for survival were evaluated. Results The median age was 65 years (min: 26-max: 88). There were 58 (41.1%) hepatitis B virus (HBV) positive, 20 (14.2%) hepatitis C (HCV) positive and 63 (44.7%) patients with no history of hepatitis. Cut-off values of ALBI score and lymphocyte-associated inflammation markers were found by receiver operating characteristic analysis. ALBI (p<0.001), aspartate aminotransferase-to-lymphocyte ratio (ALRI) (p<0.001), prognostic nutritional index (PNI) (p=0.030), hemoglobin, albumin, lymphocyte, and platelet score (HALP) (p=0.003) scores were significantly associated with survival. In multivariate analysis, being >= 65 years old [hazard ratios (HR): 2.13; 95% confidence interval (CI): 1.44-3.17; p<0.001], ALRI >= 30.79 (HR: 2.14; 95% CI: 1.20-3.82; p=0.009) predicted an increased risk of death and ALBI >=-2.54 (HR: 0.44, 95% CI: 0.29-0.69; p<0.001) predicted a decreased risk of death. Being >= 65 years old (HR: 174, 95% CI: 1.18-2.56; p=0.005) increased the risk of progression. Conclusion This study supports the statistically significant association of ALBI score and lymphocyte-associated inflammation markers (ALRI, PNI, HALP) with OS and PFS in advanced HCC patients. It is thought that this study will contribute to the literature and clinical practice. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Galenos Publ House | en_US |
dc.relation.ispartof | Namik Kemal Medical Journal | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | HCC | en_US |
dc.subject | ALBI score | en_US |
dc.subject | lymphocyte-associated inflammatory marker | en_US |
dc.subject | ALRI | en_US |
dc.subject | survival | en_US |
dc.subject | Cancer | en_US |
dc.subject | Cytokines | en_US |
dc.title | Prognostic value of albi score and lymphocyte-associated inflammation markers in advanced hepatocellular carcinoma: a single centre retrospective cross-sectional study | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 12 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.startpage | 155 | en_US |
dc.identifier.endpage | 162 | en_US |
dc.department | Pamukkale University | en_US |
dc.identifier.doi | 10.4274/nkmj.galenos.2024.93898 | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.trdizinid | 1282776 | en_US |
dc.identifier.wos | WOS:001325743200002 | en_US |
dc.institutionauthor | … | - |
item.languageiso639-1 | en | - |
item.openairetype | Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | With Fulltext | - |
item.grantfulltext | open | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
Appears in Collections: | Tıp Fakültesi Koleksiyonu TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
155-162.pdf | 1.4 MB | Adobe PDF | View/Open |
CORE Recommender
Page view(s)
88
checked on Feb 8, 2025
Download(s)
42
checked on Feb 8, 2025
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.